Immuno-Oncology Innovation

Samyang Biopharm USA

Samyang Biopharm USA, Inc. is the established subsidiary of Samyang Biopharmaceuticals Corporation (Korea) specializing in global biologics development in oncology and rare disease. We seek global in-license rights to late preclinical to Phase 1 antibodies, antibody drug conjugates and recombinant proteins for clinical development with a focus on US Phase 1 trials.

News

Samyang Biopharm USA, Inc. and Spanish National Research Council (CSIC) Announce Strategic Collaboration to Study SYB-010; A First-in-Class, Immune Stimulatory Monoclonal Antibody